4.5 Interaction with other medicinal  products and other forms of interaction  
 No drug- drug interactions were observed between ramucirumab and paclitaxel. The pharmacokinetics of paclitaxel were not affected when co- administered with ramucirumab and the pharmacokinetics of ramucirumab were not affected when co -administered with paclitaxel. The pharmacokinetics of irinotecan and its active metabolite, SN -38, were not affected when co -administered with ramucirumab . The pharmacokinetics of docetaxel  or erlotinib  were  not affected when co -administered with ramucirumab.  
 
